Bertil Lindmark
Chief Medical Officer
Cancer
ASLAN
Singapore
Biography
Dr Bertil Lindmark is Chief Medical Officer of ASLAN Pharmaceuticals. In his most recent position as Executive Director of Research and Development and Member of the Board of Directors at Almirall, a European pharmaceutical company with global reach, he led the global R&D team of more than 500 R&D staff across three sites, focusing on respiratory, gastrointestinal, dermatology and neuroscience. He secured EU and US approval of several important new drugs, including Eklira/Tudorza, Constella and Eklira/formoterol, and was instrumental in the USD$2bn sale of Almirall’s respiratory franchise to AstraZeneca.
Research Interest
Cancer
